-
Lexicon Pharma Offers 'A 2-Part Story With Upside Prospects'
Friday, October 7, 2016 - 10:45am | 439Read More...H.C. Wainwright has started coverage of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) with a Buy rating and $26 price target on potential upside from telotristat in carcinoid syndrome and sotagliflozin for type 1 diabetes. "We would be buyers of LXRX going into the December readout of the second...
-
Mirna's Murky Clinical Strategy Leaves HC Wainwright Hesitant
Friday, September 23, 2016 - 10:04am | 401Read More...HC Wainwright has downgraded Mirna Therapeutics Inc (NASDAQ: MIRN) to Neutral from Buy as it awaits further steps from the company following the voluntary stop of the MRX34 trial, the company's investigational microRNA therapy for multiple cancers. Mirna stopped its Phase 1 study of MRX34 following...
-
HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target
Thursday, September 22, 2016 - 10:45am | 441Read More...HC Wainwright has started coverage of Oncomed Pharmaceuticals Inc (NASDAQ: OMED) shares with a Buy rating. The firm sees 68 percent potential upside for the pharmaceutical company on upcoming opt-in decisions for its lead drug candidates expected from three partners: Celgene Corporation (NASDAQ:...
-
Soaring +11% In Pre-Market, Rigel Receives Buy Initiation Amid Fostamatinib Phase 3 Optimism
Wednesday, July 13, 2016 - 9:24am | 285Read More...The first Phase 3 trials for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)'s Syk inhibitor are expected to be announced in August as many investors and analysts prepare for the results. H.C. Wrainwright's Positive Take On Phase 3 H.C. Wainwright & Co's Shaunak Deepak initiated Rigel...
-
Jefferies: MannKind's Consumer Ads For Afrezza May Increase Awareness
Thursday, June 4, 2015 - 1:36pm | 343Read More...MannKind Corporation (NASDAQ: MNKD)'s plans for direct-to-consumer advertising for its Afrezza inhaled insulin product may gradually increase awareness of the product, an analyst said Thursday. The biopharma company recently traded at $5.93, up about 7 percent. Early sales of Afrezza have...
-
JP Morgan Downgrades MannKind; Jefferies Also Comments
Monday, May 11, 2015 - 12:16pm | 337Read More...JP Morgan downgraded MannKind Corporation (NASDAQ: MNKD) Monday from Neutral to Underweight following Friday’s earnings release. Analysts led by Cory Kasimov noted that sales of Afrezza had been slow with Q1 sales coming in at approximately $1.1 million. “What’s more...
-
Jefferies Expects Exciting 2015 For MannKind
Thursday, February 26, 2015 - 11:56am | 241Read More...With the initial Afrezza launch recently commencing, MannKind Corporation (NASDAQ: MNKD) has already seen encouraging sales steps despite management stating that sales would initially be "slow and steady." Early feedback from Sanofi SA (ADR) (NYSE: SNY) is that demand has been higher...
-
Jefferies & Company Raises Incyte (INCY) Target Price To $19
Tuesday, March 23, 2010 - 9:28am | 144Read More...Jefferies & Company analysts Thomas Wei, Thomas Nguyen and Shaunak Deepak maintained their Buy rating for shares of Incyte Corporation (Nasdaq: INCY) and raised the price target from $13 to $19 per share. The analysts spoke to three of Incyte Corporation's investigators about the prospects of...
-
Jefferies & Company Raises ViroPharma (VPHM) Price Target To $18
Monday, March 22, 2010 - 12:51pm | 177Read More...Jefferies & Company analysts Thomas Wei, Shaunak Deepak and Thomas Nguyen rated shares of ViroPharma Incorporated (Nasdaq: VPHM) a Buy and raised the price target from $16 to $18. The analysts said that there were a number of ways ViroPharma Incorporated would benefit from health care reform....
-
Jefferies & Company Maintains Auxilium Pharmaceuticals (AUXL) Buy Rating
Monday, March 22, 2010 - 12:10pm | 119Read More...Jefferies & Company analysts Thomas Wei, Shaunak Deepak and Thomas Nguyen rated shares of Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) a Buy, with a price target of $44. The analysts said that like many biotech companies, Auxilium Pharmaceuticals, Inc is set to benefit greatly from health care...
